DK1514546T3 - Lægemiddelsammensætninger på basis af tiotropiumsalte og salte af salmeterol - Google Patents

Lægemiddelsammensætninger på basis af tiotropiumsalte og salte af salmeterol

Info

Publication number
DK1514546T3
DK1514546T3 DK04028508T DK04028508T DK1514546T3 DK 1514546 T3 DK1514546 T3 DK 1514546T3 DK 04028508 T DK04028508 T DK 04028508T DK 04028508 T DK04028508 T DK 04028508T DK 1514546 T3 DK1514546 T3 DK 1514546T3
Authority
DK
Denmark
Prior art keywords
salts
salmeterol
tiotropium
pharmaceutical compositions
compositions based
Prior art date
Application number
DK04028508T
Other languages
English (en)
Inventor
Juergen Dr Nagel
Hilke Nagel
Christel Dr Schmelzer
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1514546T3 publication Critical patent/DK1514546T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK04028508T 2000-11-13 2001-11-09 Lægemiddelsammensætninger på basis af tiotropiumsalte og salte af salmeterol DK1514546T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10056104A DE10056104A1 (de) 2000-11-13 2000-11-13 Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
PCT/EP2001/012962 WO2002038154A1 (de) 2000-11-13 2001-11-09 Neue arzneimittelkompositionen auf der basis von tiotropiumsalzen und salzen des salmeterols

Publications (1)

Publication Number Publication Date
DK1514546T3 true DK1514546T3 (da) 2007-09-24

Family

ID=7663071

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01989446T DK1335728T3 (da) 2000-11-13 2001-11-09 Lægemiddelsammensætninger på basis af tiotropiumsalte og salmeterolsalte
DK04028508T DK1514546T3 (da) 2000-11-13 2001-11-09 Lægemiddelsammensætninger på basis af tiotropiumsalte og salte af salmeterol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01989446T DK1335728T3 (da) 2000-11-13 2001-11-09 Lægemiddelsammensætninger på basis af tiotropiumsalte og salmeterolsalte

Country Status (32)

Country Link
EP (3) EP1514546B1 (da)
JP (2) JP4282322B2 (da)
KR (2) KR100940752B1 (da)
CN (1) CN1678318A (da)
AT (2) ATE291428T1 (da)
AU (3) AU2002227910B2 (da)
BG (1) BG107781A (da)
BR (1) BR0115226A (da)
CA (1) CA2429012A1 (da)
CY (1) CY1106774T1 (da)
CZ (1) CZ20031444A3 (da)
DE (3) DE10056104A1 (da)
DK (2) DK1335728T3 (da)
EA (1) EA007904B1 (da)
EC (1) ECSP034571A (da)
EE (1) EE200300228A (da)
ES (2) ES2287629T3 (da)
HR (1) HRP20030378A2 (da)
HU (1) HUP0301447A3 (da)
IL (2) IL155718A0 (da)
MX (1) MXPA03004164A (da)
NO (1) NO20032111L (da)
NZ (1) NZ526400A (da)
PL (1) PL205330B1 (da)
PT (2) PT1335728E (da)
RS (2) RS20090105A (da)
SG (1) SG167657A1 (da)
SI (2) SI1335728T1 (da)
SK (2) SK286950B6 (da)
UA (1) UA74853C2 (da)
WO (1) WO2002038154A1 (da)
ZA (1) ZA200302921B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ATE286716T1 (de) * 1999-11-23 2005-01-15 Glaxo Group Ltd Pharmazeutische formulierungen enthaltend salmeterol
WO2003024452A1 (de) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur inhalation
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10256080A1 (de) * 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropiumhaltige Arzneimittelkombination für die Inhalation
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
CA2510043A1 (en) * 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing hfc solution formulations
DE10351663A1 (de) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
DE10345065A1 (de) * 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum
AU2004285683C1 (en) * 2003-11-03 2011-09-08 Boehringer Ingelheim International Gmbh Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
AU2004285685B2 (en) * 2003-11-03 2011-03-24 Boehringer Ingelheim International Gmbh Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
PL1891974T3 (pl) * 2004-05-31 2010-12-31 Almirall Sa Kombinacje zawierające środki przeciwmuskarynowe i inhibitory PDE4
BRPI0609295A2 (pt) 2005-05-02 2010-03-23 Boehringer Ingelheim Int formas cristalinas de brometo de tiotràpio, composiÇço farmacÊutica, uso e mÉtodo para preparar as mesmas
CA2617897A1 (en) * 2005-08-06 2007-02-15 Boehringer Ingelheim International Gmbh Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US20120220557A1 (en) * 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2819669B1 (de) * 2012-02-28 2021-04-21 Boehringer Ingelheim International GmbH Neue treibgashaltige tiotropium-formulierung
WO2015065222A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Фармацевтический ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких, содержащий в качестве активного вещества микронизированный тиотропия бромид, и способ его получения
TW201835041A (zh) 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
CN111971034A (zh) * 2018-07-26 2020-11-20 四川海思科制药有限公司 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
CN116173025A (zh) * 2018-07-26 2023-05-30 四川海思科制药有限公司 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
US11642372B2 (en) 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
WO2022119661A1 (en) * 2020-12-04 2022-06-09 Tygrus, LLC THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4570251B2 (ja) * 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
DE19847971A1 (de) * 1998-10-17 1999-09-02 Schiering Verfahren und Einrichtung zur Verhinderung von Filterbränden (Staubfilter)
DE19847970A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähige Wirkstoff-Formulierung
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator

Also Published As

Publication number Publication date
CZ20031444A3 (cs) 2003-08-13
KR20030065509A (ko) 2003-08-06
ECSP034571A (es) 2003-06-25
SK286939B6 (sk) 2009-07-06
JP2005068163A (ja) 2005-03-17
SK7412003A3 (en) 2003-10-07
RS50286B (sr) 2009-09-08
DE10056104A1 (de) 2002-05-23
ATE291428T1 (de) 2005-04-15
ES2287629T3 (es) 2007-12-16
SK286950B6 (sk) 2009-08-06
ZA200302921B (en) 2004-04-19
EP1514546B1 (de) 2007-05-23
PL205330B1 (pl) 2010-04-30
HUP0301447A2 (hu) 2003-10-28
HUP0301447A3 (en) 2007-10-29
CY1106774T1 (el) 2012-05-23
HRP20030378A2 (en) 2005-04-30
IL155718A (en) 2010-06-30
UA74853C2 (en) 2006-02-15
SI1514546T1 (sl) 2007-10-31
NO20032111D0 (no) 2003-05-12
SG167657A1 (en) 2011-01-28
JP2004513146A (ja) 2004-04-30
WO2002038154A1 (de) 2002-05-16
NZ526400A (en) 2005-09-30
EP1335728B1 (de) 2005-03-23
BR0115226A (pt) 2003-10-07
EA200300503A1 (ru) 2004-12-30
PT1335728E (pt) 2005-05-31
EA007904B1 (ru) 2007-02-27
KR100886094B1 (ko) 2009-02-27
SI1335728T1 (en) 2005-08-31
PT1514546E (pt) 2007-06-15
DE50112535D1 (de) 2007-07-05
YU35503A (sh) 2006-05-25
EP1514546A1 (de) 2005-03-16
AU2007202303B2 (en) 2010-01-21
BG107781A (bg) 2004-06-30
KR20080079701A (ko) 2008-09-01
KR100940752B1 (ko) 2010-02-11
PL365989A1 (en) 2005-01-24
RS20090105A (en) 2009-07-15
NO20032111L (no) 2003-07-08
MXPA03004164A (es) 2005-08-16
JP4282322B2 (ja) 2009-06-17
AU2007202303A1 (en) 2007-06-14
IL155718A0 (en) 2003-11-23
JP4282594B2 (ja) 2009-06-24
EP1335728A1 (de) 2003-08-20
CN1678318A (zh) 2005-10-05
AU2791002A (en) 2002-05-21
DK1335728T3 (da) 2005-04-18
EE200300228A (et) 2003-10-15
CA2429012A1 (en) 2002-05-16
EP1808174A1 (de) 2007-07-18
ATE362761T1 (de) 2007-06-15
ES2240549T3 (es) 2005-10-16
DE50105729D1 (de) 2005-04-28
AU2002227910B2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
DK1514546T3 (da) Lægemiddelsammensætninger på basis af tiotropiumsalte og salte af salmeterol
HK1091121A1 (en) Substituted 2-aminotetralins for the treatment of depressions
NO20022334D0 (no) Ny sammensetning og anvendelse
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
WO2002032898A3 (de) Neue anticholinergika, verfahren zu deren herstellung und deren verwendung als arzneimittel
NO20054787D0 (no) Indenderivater som farmasotiske midler
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20073551L (no) Nikotinacetylkolinreseptorligander
ATE290534T1 (de) 4-(oxadiazol-3-yl)-1,4-diazabizyklo(3.2.2)- nonanderivate, ihre herstellung und therapeutische verwendung
HK1129111A1 (en) Tiotropium salts, pharmaceutical formulations containing the salts and the use thereof
IS7766A (is) N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
DK1246789T3 (da) Fremgangsmåde til fremstilling af optisk ren (R)- og (S)-didesmethylsibutramin
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
ATE389405T1 (de) Fexofenadine hydrochlorid polymorph
HK1086819A1 (en) 2-(butyl-1-sulfonylamino)-n-(1(r)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
DK1265856T3 (da) Hidtil ukendt fremgangsmåde til fremstillingen af alpha-(2,4-disulfophenyl)-N-tert-butylnitron og farmaceutisk acceptable salte deraf
NZ512684A (en) Salts of (R)- or (S)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide useful in treating central nervous system disorders
DE50107490D1 (de) Stoffgemisch enthaltend bisphenol a
NO20000199D0 (no) Medikamenter inneholdende polyhydroksybutylpyraziner, nye polyhydroksybutylpyraziner og deres fremstilling
SE0403117D0 (sv) New compounds 1
DK1370529T3 (da) Substituerede dimethyl-[-1(1-phenyl-cyclohexyl)-piperidin-3-ylmethyl]-aminer og anvendelse som analgetika
IT1318650B1 (it) 1,3-diossolani ad attivita' antitosse.
ATE306940T1 (de) Zusammensetzung gegen coccidiose